Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 10 December, 2024
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 500674 | NSE: SANOFI

Sanofi India Ltd: Intrinsic Value and Fundamental Analysis

Share Price and Basic Stock Data

Last Updated: December 9, 2024, 10:16 pm

Market Cap 14,523 Cr.
Current Price 6,302
High / Low7,600/4,606
Stock P/E34.4
Book Value 298
Dividend Yield2.65 %
ROCE71.1 %
ROE51.5 %
Face Value 10.0
PEG Ratio16.38

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Sanofi India Ltd

Competitors of Sanofi India Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Gujarat Themis Biosyn Ltd 3,608 Cr. 331390/10868.5 20.50.20 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 60.2 Cr. 81.294.9/26.623.1 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 27.8 Cr. 19.019.5/8.3536.1 6.640.00 %2.65 %2.08 % 10.0
Godavari Drugs Ltd 95.5 Cr. 127155/87.014.3 55.40.00 %12.7 %15.5 % 10.0
Glenmark Life Sciences Ltd 12,639 Cr. 1,0301,335/62729.8 2072.18 %28.1 %21.1 % 2.00
Industry Average19,709.05 Cr1,260.2658.76184.910.31%16.36%16.88%6.61

All Competitor Stocks of Sanofi India Ltd

Quarterly Result

MonthJun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Sales789754688707699692672736515715694511464
Expenses542556561512538510505507393506506374348
Operating Profit247199127194161182167230122208187137116
OPM %31%26%18%28%23%26%25%31%24%29%27%27%25%
Other Income1750416142161134445712124121
Interest0000000010000
Depreciation21141111111010109101099
Profit before tax243688132326166182190264169210189169127
Tax %26%23%32%27%27%28%31%28%27%28%27%19%19%
Net Profit17853090238120131131190123152138137103
EPS in Rs77.52230.3539.30103.6552.3556.9156.9182.7853.4366.1759.8759.3944.96

Last Updated: October 25, 2024, 4:12 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: October 25, 2024, 4:12 pm

MonthDec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023TTM
Sales1,5731,8091,9772,1932,3672,4602,7713,0712,9022,9572,7702,8512,383
Expenses1,2611,4111,6391,8171,8321,9212,1462,4032,1862,1942,0662,0471,734
Operating Profit312398339376535538625667716762704804649
OPM %20%22%17%17%23%22%23%22%25%26%25%28%27%
Other Income418313121866798833455642048386
Interest1000211022221
Depreciation9092971131191021031008267424038
Profit before tax2623883734814805156106006771,258864846695
Tax %32%32%29%33%37%37%38%31%29%25%28%29%
Net Profit177265264322304326381414478944621603530
EPS in Rs76.81115.30114.61139.78132.26141.74165.48180.09207.65410.61269.83262.26230.39
Dividend Payout %43%39%39%46%51%50%51%194%176%119%211%64%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year
YoY Net Profit Growth (%)
Change in YoY Net Profit Growth (%)

No data available for trend analysis.

Growth

Compounded Sales Growth
10 Years:5%
5 Years:1%
3 Years:-1%
TTM:-9%
Compounded Profit Growth
10 Years:9%
5 Years:9%
3 Years:5%
TTM:-9%
Stock Price CAGR
10 Years:12%
5 Years:8%
3 Years:10%
1 Year:26%
Return on Equity
10 Years:22%
5 Years:27%
3 Years:33%
Last Year:52%

Last Updated: Unknown

Balance Sheet

Last Updated: Unknown

MonthDec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Jun 2024
Equity Capital23232323232323232323232323
Reserves1,1811,3241,4631,6041,8602,0032,1962,4192,0962,2031,253992662
Borrowings000000002325241922
Other Liabilities427532742778658751765802777811772681654
Total Liabilities1,6311,8782,2282,4052,5412,7782,9843,2442,9183,0612,0721,7151,360
Fixed Assets699699648877817769733499464334306315302
CWIP4313621022343021171013241629
Investments0000000000020
Other Assets8881,0431,3691,5051,6901,9782,2302,7282,4442,7141,7431,3821,029
Total Assets1,6311,8782,2282,4052,5412,7782,9843,2442,9183,0612,0721,7151,360

Reserves and Borrowings Chart

Cash Flow

MonthDec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023
Cash from Operating Activity +290273265213322435374412611559399231
Cash from Investing Activity +-5-3356136-155-79-736627663165136
Cash from Financing Activity +-90-105-122-147-180-188-197-183-810-849-1,583-878
Net Cash Flow195-168205102-1316810429578341-533-612

Free Cash Flow

MonthDec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023
Free Cash Flow312.00398.00339.00376.00535.00538.00625.00667.00693.00737.00680.00785.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthDec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023
Debtor Days232421242229212719181717
Inventory Days135151179173169151154127107110125202
Days Payable758312281791191101009310510989
Cash Conversion Cycle839278115112616554332233130
Working Capital Days34326979171835-7-19-1825
ROCE %23%29%22%26%27%26%29%28%32%35%41%71%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
Promoters60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%
FIIs9.22%8.99%8.71%8.26%6.99%6.71%6.72%6.80%6.31%6.11%5.81%5.78%
DIIs19.05%18.65%18.59%18.28%19.22%19.46%19.65%21.68%22.51%22.88%22.60%22.62%
Public11.33%11.96%12.30%13.08%13.41%13.43%13.22%11.10%10.78%10.61%11.21%11.20%
No. of Shareholders50,91659,27664,54273,73474,59376,69471,51368,59862,87061,84967,66266,211

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Aditya Birla Sun Life Frontline Equity Fund268,5080.84216.62100,8372024-12-09166.28%
Nippon India Pharma Fund236,0082.94190.4100,8372024-12-09134.05%
Nippon India Growth Fund226,7660.78182.94100,8372024-12-09124.88%
Nippon India Small Cap Fund196,3420.36158.4100,8372024-12-0994.71%
SBI Contra Fund161,0000.68129.5100,8372024-12-0959.66%
Nippon India Multi Cap Fund152,3710.5122.93100,8372024-12-0951.11%
SBI Long Term Equity Fund147,9880.69119.04100,8372024-12-0946.76%
Aditya Birla Sun Life Small Cap Fund144,4332.22116.52100,8372024-12-0943.23%
SBI Magnum Midcap Fund100,8370.5681.11100,8372024-12-090%
Aditya Birla Sun Life Multi-Cap Fund87,3421.4370.46100,8372024-12-09-13.38%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthDec 23
FaceValue10.00
Basic EPS (Rs.)261.78
Diluted EPS (Rs.)261.78
Cash EPS (Rs.)279.35
Book Value[Excl.RevalReserv]/Share (Rs.)441.39
Book Value[Incl.RevalReserv]/Share (Rs.)441.39
Revenue From Operations / Share (Rs.)1239.61
PBDIT / Share (Rs.)377.83
PBIT / Share (Rs.)360.61
PBT / Share (Rs.)367.61
Net Profit / Share (Rs.)262.13
NP After MI And SOA / Share (Rs.)262.13
PBDIT Margin (%)30.47
PBIT Margin (%)29.09
PBT Margin (%)29.65
Net Profit Margin (%)21.14
NP After MI And SOA Margin (%)21.14
Return on Networth / Equity (%)59.38
Return on Capital Employeed (%)77.98
Return On Assets (%)35.15
Current Ratio (X)1.92
Quick Ratio (X)0.89
Dividend Payout Ratio (NP) (%)139.85
Dividend Payout Ratio (CP) (%)131.23
Earning Retention Ratio (%)-39.85
Cash Earning Retention Ratio (%)-31.23
Interest Coverage Ratio (X)511.18
Interest Coverage Ratio (Post Tax) (X)345.18
Enterprise Value (Cr.)18147.83
EV / Net Operating Revenue (X)6.37
EV / EBITDA (X)20.88
MarketCap / Net Operating Revenue (X)6.51
Retention Ratios (%)-39.85
Price / BV (X)18.28
Price / Net Operating Revenue (X)6.51
EarningsYield0.03

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Sanofi India Ltd as of December 10, 2024 is: 5,419.27

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of December 10, 2024, Sanofi India Ltd is Overvalued by 14.01% compared to the current share price 6,302.00

Intrinsic Value of Sanofi India Ltd as of December 10, 2024 is: 5,533.08

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of December 10, 2024, Sanofi India Ltd is Overvalued by 12.20% compared to the current share price 6,302.00

Last 5 Year EPS CAGR: 2.10%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 32.42%, which is a positive sign.
  2. The stock has a low average Working Capital Days of 17.58, which is a positive sign.
  3. The company has higher reserves (1,635.08 cr) compared to borrowings (8.69 cr), indicating strong financial stability.
  4. The company has shown consistent growth in sales (1.85 cr) and profit (522.46 cr) over the years.
  1. The stock has a high average Cash Conversion Cycle of 73.17, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sanofi India Ltd:
    1. Net Profit Margin: 21.14%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 77.98% (Industry Average ROCE: 16.21%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 59.38% (Industry Average ROE: 16.41%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 345.18
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.89
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 34.4 (Industry average Stock P/E: 47.44)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Sanofi India Ltd. is a Public Limited Listed company incorporated on 02/05/1956 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1956PLC009794 and registration number is 009794. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 2956.60 Cr. and Equity Capital is Rs. 23.00 Cr. for the Year ended 31/12/2021.
INDUSTRYADDRESSCONTACT
PharmaceuticalsSanofi House, Mumbai Maharashtra 400072igrc.sil@sanofi.com
http://www.sanofiindialtd.com
Management
NamePosition Held
Mr. Aditya NarayanChairman & Ind.Director
Mr. Rodolfo HroszManaging Director
Mr. Rachid AyariWholeTime Director & CFO
Ms. Renee AmonkarWhole Time Director
Mr. Vaibhav KarandikarNon Executive Director
Mrs. Usha ThoratIndependent Director
Mr. Rahul BhatnagarIndependent Director

FAQ

What is the latest intrinsic value of Sanofi India Ltd?

The latest intrinsic value of Sanofi India Ltd as on 10 December 2024 is ₹5419.27, which is 14.01% lower than the current market price of ₹6,302.00. The stock has a market capitalization of 14,523 Cr. and recorded a high/low of ₹7,600/4,606 during the current fiscal year 2024-2025. As of Jun 2024, the company has reserves of ₹662 Cr and total liabilities of ₹1,360 Cr.

What is the Market Cap of Sanofi India Ltd?

The Market Cap of Sanofi India Ltd is 14,523 Cr..

What is the current Stock Price of Sanofi India Ltd as on 10 December 2024?

The current stock price of Sanofi India Ltd as on 10 December 2024 is 6,302.

What is the High / Low of Sanofi India Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Sanofi India Ltd stocks is 7,600/4,606.

What is the Stock P/E of Sanofi India Ltd?

The Stock P/E of Sanofi India Ltd is 34.4.

What is the Book Value of Sanofi India Ltd?

The Book Value of Sanofi India Ltd is 298.

What is the Dividend Yield of Sanofi India Ltd?

The Dividend Yield of Sanofi India Ltd is 2.65 %.

What is the ROCE of Sanofi India Ltd?

The ROCE of Sanofi India Ltd is 71.1 %.

What is the ROE of Sanofi India Ltd?

The ROE of Sanofi India Ltd is 51.5 %.

What is the Face Value of Sanofi India Ltd?

The Face Value of Sanofi India Ltd is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Sanofi India Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE